Genomic Health to Announce Third Quarter 2013 Financial Results and Host Conference Call on Tuesday, November 5, 2013

   Genomic Health to Announce Third Quarter 2013 Financial Results and Host
                 Conference Call on Tuesday, November 5, 2013

PR Newswire

REDWOOD CITY, Calif., Oct. 29, 2013

REDWOOD CITY, Calif., Oct. 29, 2013 /PRNewswire/ --Genomic Health,
Inc.(Nasdaq: GHDX) today announced that the company will host a conference
call and webcast onTuesday, November 5 at4:30 p.m. Eastern Timeto discuss
its third quarter 2013 financial results. The call and webcast will follow
the release of the third quarter financial results after market close.


Conference Call Details
To access the live conference call on November 5 at 4:30 p.m. Eastern Time via
phone, please dial (877) 303-7208 from the United States and Canada or +1(224)
357-2389 internationally. Please dial in approximately ten minutes prior to
the start of the call.

To access the live and subsequently archived webcast of the conference call,
go to theInvestor Relationssection of the company's website at Please connect to the website at least 15
minutes prior to the call to allow for any software download that may be

About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of
genomic-based diagnostic tests that address the overtreatment of early stage
cancer, one of the greatest issues in healthcare today. The company is
applying its world-class scientific and commercial expertise and
infrastructure to lead the translation of massive amounts of genomic datainto
clinically-actionable results throughout the cancer patient's journey, from
screening and surveillance, to diagnosis, to treatment selection and
monitoring. Genomic Health's  lead product, the Oncotype  DX^® breast cancer
test, has been shown to predict the likelihood of chemotherapy benefit as well
as recurrence in invasive breast cancer and has been shown to predict the
likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to
this widely adopted test, Genomic Health provides the Oncotype  DX colon
cancer test, the first multi-gene expression test developed for the assessment
of risk of recurrence in patients with stage II and stage III disease, and the
Oncotype  DX prostate cancer test, which predicts disease aggressiveness in
men with low risk disease. As of June 30, 2013, more than 19,000 physicians in
over 70 countries had ordered more than 375,000 Oncotype  DX tests. The
company is based in Redwood City, California with European headquarters in
Geneva, Switzerland. For more information, please visit,
and follow the company on Twitter: @GenomicHealth. To learn more about
OncotypeDX tests, visit:,

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
relating to the attributes and focus of the company's product pipeline; the
applicability of clinical study results to actual outcomes; the potential
economic benefits associated with the company's tests; the ability of the
company to develop additional tests in the future; the demand for the
company's tests; the ability of any potential tests the company may develop to
optimize cancer treatment and the Company's ability to launch new tests in new
markets and expand internationally. Forward-looking statements are subject to
risks and uncertainties that could cause actual results to differ materially,
and reported results should not be considered as an indication of future
performance. These risks and uncertainties include, but are not limited to:
the risks and uncertainties associated with the regulation of the company's
tests; the results of clinical studies; the applicability of clinical study
results to actual outcomes; our ability to develop and commercialize new
tests; unanticipated costs or delays in research and development efforts; our
ability to obtain capital when needed and the other risks set forth in the
company's filings with the Securities and Exchange Commission, including the
risks set forth in the company's Quarterly Report on Form 10-Q for the period
ended June 30, 2013. These forward-looking statements speak only as of the
date hereof. Genomic Health disclaims any obligation to update these
forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and
DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All
other trademarks and service marks are the property of their respective

SOURCE Genomic Health, Inc.

Contact: Investors: Dean Schorno, Genomic Health, 650-569-2281,, Media: Emily Faucette, Genomic Health,
Press spacebar to pause and continue. Press esc to stop.